The National Institute for Health and Care Excellence (NICE) has published new draft guidance recommending risdiplam – also called Evrysdi™ and made by Roche – for the treatment of spinal muscular atrophy (SMA), as part of a managed access agreement (MAA).
The MAA is a special arrangement between National Health Service (NHS) England and NHS Improvement and the company Roche. It will allow people to access treatment with risdiplam while more data is collected to address the uncertainties identified by the independent NICE committee. After this, NICE will decide whether or not to recommend it for routine use on the NHS and update the guidance. NICE added that it will be available through the MAA until then.
Read more at: https://www.europeanpharmaceuticalreview.com/news/165751/nice-recommends-risdiplam-for-spinal-muscular-atrophy/
